Format

Send to

Choose Destination
MAbs. 2011 Sep-Oct;3(5):415-6. doi: 10.4161/mabs.3.5.17334. Epub 2011 Sep 1.

Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies.

Abstract

Therapeutic antibodies have captured substantial attention due to the relatively high rate at which these products reach marketing approval, and the subsequent commercial success they frequently achieve. In the 2000s, a total of 20 antibodies (18 full-length IgG and 2 Fab) were approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA). In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011. However, a less heralded group of antibody-based therapeutics comprising proteins or peptides fused with an Fc is following the success of classical antibodies.

PMID:
21785279
PMCID:
PMC3225844
DOI:
10.4161/mabs.3.5.17334
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center